Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.42 | $321.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 27 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,404 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 01, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.52 | $391.20 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,338 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 01, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.52 | $423.80 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,772 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 01, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.52 | $391.20 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 13 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,262 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 28, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,324 | $6.37 | $14,803.88 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,760 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.31, inclusive. Read SEC document |
| June 28, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,278 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 28, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.49 | $421.85 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,624 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 28, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 12 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,202 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 27, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,865 | $6.35 | $11,842.75 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,084 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.31, inclusive. Read SEC document |
| June 27, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.38 | $319.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 26 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,354 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 27, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.48 | $388.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,218 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 27, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.47 | $420.55 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,575 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 27, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.48 | $388.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 11 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,142 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 21:15 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,266 | $6.40 | $8,102.40 |
DisclosureSEC source: 0001209191-19-039526 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,949 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.44 to $6.38, inclusive. Read SEC document |
| June 26, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.54 | $392.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,158 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 26, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.53 | $424.45 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,499 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 26, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.54 | $392.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 10 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,082 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 25, 2019 Filed Jun 28, 2019 21:15 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,310 | $6.44 | $14,876.40 |
DisclosureSEC source: 0001209191-19-039526 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,215 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.40, inclusive. Read SEC document |
| June 25, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.46 | $323.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 25 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 25, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.56 | $393.60 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,098 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 25, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.55 | $425.75 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,427 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 25, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.56 | $393.60 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 9 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,022 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 24, 2019 Filed Jun 28, 2019 21:15 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 4,000 | $6.36 | $25,440.00 |
DisclosureSEC source: 0001209191-19-039526 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,525 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.20, inclusive. Read SEC document |
| June 24, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.54 | $392.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,038 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 24, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.53 | $424.45 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,402 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 24, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.54 | $392.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 8 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,962 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 21, 2019 Filed Jun 28, 2019 21:15 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 3,794 | $6.22 | $23,598.68 |
DisclosureSEC source: 0001209191-19-039526 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,525 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.15, inclusive. Read SEC document |
| June 21, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.24 | $312.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 24 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,254 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 21, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.34 | $380.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,978 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 21, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.33 | $411.45 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,346 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 21, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.34 | $380.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 7 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,902 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 20, 2019 Filed Jun 28, 2019 21:15 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,894 | $6.19 | $11,723.86 |
DisclosureSEC source: 0001209191-19-039526 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,319 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive. Read SEC document |
| June 20, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.33 | $379.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 20, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.32 | $410.80 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,249 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 20, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.33 | $379.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 6 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,842 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:26 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,610 | $6.19 | $9,965.90 |
DisclosureSEC source: 0001209191-19-038591 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,213 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive. Read SEC document |
| June 19, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.25 | $312.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 23 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,204 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 19, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.35 | $381.00 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,858 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 19, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.34 | $412.10 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,213 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 19, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.35 | $381.00 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 5 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,782 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 18, 2019 Filed Jun 21, 2019 21:26 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,656 | $6.22 | $10,300.32 |
DisclosureSEC source: 0001209191-19-038591 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,923 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.19, inclusive. Read SEC document |
| June 18, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.36 | $381.60 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,798 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 18, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.35 | $412.75 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,193 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 18, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.36 | $381.60 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 4 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,722 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 17, 2019 Filed Jun 21, 2019 21:26 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,050 | $6.19 | $12,689.50 |
DisclosureSEC source: 0001209191-19-038591 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,479 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. Read SEC document |
| June 17, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.23 | $311.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 22 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,154 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 17, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.33 | $379.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,738 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 17, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.32 | $410.80 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,163 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 17, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.33 | $379.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 3 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,662 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 14, 2019 Filed Jun 21, 2019 21:26 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,859 | $6.24 | $11,600.16 |
DisclosureSEC source: 0001209191-19-038591 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,529 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.20, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.